阿立哌唑治疗自闭症谱系障碍共患行为问题的临床分析

Clinical analysis of aripiprazole in the treatment of comorbidity behavior of autism-spectrum disorders

目的探讨阿立哌唑治疗自闭症谱系障碍(ASD)儿童共患行为问题的临床疗效和安全性。方法收集该中心确诊的ASD共患行为问题突出且韦氏智力测试总智商大于或等于70分的患儿20例,使用阿立哌唑治疗8周。治疗前和治疗后8周分别采用临床疗效总评价量表(CGI)中的病情严重程度分量表(SI)、孤独症治疗评估量表(ATEC)和CONNER父母评定量表进行临床疗效评定,采用副反应量表(TESS)进行药物副作用评定。于治疗前和治疗后8周分别进行血尿常规、心电图、肝肾功能、血糖和体质量等检查。结果阿立哌唑最低剂量2.50mg/d,最高剂量20.00mg/d,平均(8.50±3.25)mg/d。与治疗前比较,治疗后8周患者SI评分、ATEC总分及其行为、感知项评分下降,差异均有统计学意义(P<0.05);治疗前后语言和社交项比较,差异均无统计学意义(P>0.05)。与治疗前比较,治疗后8周患者CONNER父母评定量表的多动、多动-冲动评分下降,差异均有统计学意义(P<0.05)。结论阿立哌唑对ASD共患行为问题改善疗效好,安全性高。

Objective To explore the clinical efficacy and safety of aripiprazole in the treatment of comorbidity behaviors in children with autism spectrum disorders(ASD).Methods A total of 20 children,with Webster Intelligence Test score of greater than or equal to 70 points,diagnosed with ASD and behavior problems in this center were collected and treated with aripiprazole for 8 weeks.Before and 8 weeks after treatment,The severity of illness(SI)scale which was a part of clinical global impression(CGI)scale,autism treatment evaluation checklist(ATEC)and CONNER parental questionnaire were used to evaluate the clinical efficacy.The treatment emergent symptom scale(TESS)was used to evaluate the side effects.The hematuria,electrocardiogram,liver and kidney function,blood glucose and body mass were detected before and 8 weeks after treatment.Results The lowest dose of aripiprazole was 2.50 mg/d,the highest dose was 20.00 mg/d,and the mean dose of aripiprazole was(8.50±3.25)mg/d.Compared with before treatment,the SI score,ATEC total score,behavior and perception dimension scores decreased at 8 weeks after treatment,and there were statistically significant differences(P<0.05).There was no statistically significant difference in language and social dimensions between before and 8 weeks after treatment(P>0.05).Compared with before treatment,the hyperactivity,hyperactivity-pulsation scores of CONNER parental questionnaire decreased at 8 weeks after treatment,and there were statistically significant differences(P<0.05).Conclusion Aripiprazole is effective and safe in the treatment of comorbidity in children with ASD.